Somewhat Favorable News Coverage Somewhat Unlikely to Affect Ra Pharmctl (NASDAQ:RARX) Share Price
News articles about Ra Pharmctl (NASDAQ:RARX) have trended somewhat positive recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ra Pharmctl earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.818344522504 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Ra Pharmctl (NASDAQ:RARX) opened at 14.11 on Tuesday. Ra Pharmctl has a 52 week low of $12.05 and a 52 week high of $27.84. The stock’s market capitalization is $318.42 million. The firm’s 50-day moving average price is $18.15 and its 200 day moving average price is $20.50.
Ra Pharmctl (NASDAQ:RARX) last issued its quarterly earnings results on Thursday, May 11th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.08. Analysts expect that Ra Pharmctl will post ($2.12) earnings per share for the current year.
RARX has been the topic of several recent research reports. Zacks Investment Research downgraded Ra Pharmctl from a “buy” rating to a “hold” rating in a research note on Thursday, June 29th. Jefferies Group LLC restated a “buy” rating and issued a $25.00 price target on shares of Ra Pharmctl in a research note on Wednesday, April 26th. Finally, Credit Suisse Group restated an “outperform” rating and issued a $19.00 price target on shares of Ra Pharmctl in a research note on Tuesday, April 18th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $27.00.
In other news, major shareholder Bioventures Ltd Novartis sold 42,615 shares of the company’s stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $25.90, for a total transaction of $1,103,728.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have sold 208,880 shares of company stock worth $4,946,431. Insiders own 14.50% of the company’s stock.
Ra Pharmctl Company Profile
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with MarketBeat.com's FREE daily email newsletter.